Speakers: Andrés Hurtado-Loreanzo, Ph.D. (Vice President, Translational Research at Crohn's & Colitis Foundation)
Original Broadcast date: October 28, 2021
Crohn’s disease (CD) is a heterogenous inflammatory bowel disease defined by a chronic inflammation of the gastrointestinal (GI) tract. Unfortunately, the early prediction of disease course and response to treatment is lacking. To address this unmet need, Dr. Hurtado-Lorenzo describes a longitudinal and multiomics study with the largest cohort of pediatric CD patients (n = 913) to date. Using invasive biopsy samples, gene expression analyses were first performed. Thirteen (13)-gene signatures of disease complications (i.e., fibrosis, fistulas) or response to anti-TNFα treatment were discovered with areas under the curve (AUCs) of 0.93 or 0.91, respectively. Using minimally invasive plasma samples, proteins were screened with the Olink® Target platform. Fourteen (14) proteins predictive of disease complications were identified with an AUC of 0.84. Three (3) proteins were also identified that classified responders and non-responders to treatment with an AUC of 0.90. Moreover, the inter- and intra- coefficient of variations (CVs) between Olink® runs was 7%, on average. A custom Olink® assay with these 17 proteins is currently being produced for further validation. This multiomics study revealed biological predictors of disease complications with high accuracy at the time of diagnosis, which may improve the quality of life for children with Crohn’s disease. The Olink® platform is also being used in a separate adult CD study to select which patients should be treated with anti-fibrotic drugs.
The webinar covers the following points:
If you have any questions about Olink, please contact us at info@olink.com.